A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in
participants with unresectable, non-metastatic hepatocellular carcinoma